SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as the community rallies around the OG meme coin, anticipating potential listings and partnerships. Discussions are centered on community building and expressing bullish sentiment, emphasizing the coin's potential within the meme culture landscape. The community is actively participating in raids and spaces, further amplifying the coin's visibility.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is gaining attention as a multichain meme coin, with its community emphasizing its deflationary mechanism and organic growth. Discussions highlight its presence on multiple chains like Solana, CRO, and Base, with some suggesting staking opportunities may be coming. The community is actively using "caw caw caw" to express their excitement.

Bounce Token

Bounce Token is experiencing heightened interest as the community anticipates a potential breakout, drawing comparisons to previous rallies. Discussions revolve around promising utility, growing bid sizes, and possible integration with AI, with some community members pointing to bullish technical indicators. Despite some skepticism, there's optimism for a significant run, with attention focused on key price levels.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community discusses its potential, quantum-resistant technology, and real-world asset tokenization. Bullish sentiment is fueled by anticipation of alt season and speculation around partnerships, while some express frustration with the current price action and the Algorand Foundation. Chatter also includes commentary about specific users and their past predictions.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amid discussions about potential catalysts for Bitcoin, including possible government actions and favorable seasonal patterns. Community members are actively debating entry points and whether IBIT offers a better risk/reward profile compared to holding Bitcoin directly or investing in companies with Bitcoin on their balance sheets. Some traders are highlighting options activity suggesting bullish sentiment, while others remain cautious.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community discusses the project "crow with knife" ($CAW) and its potential impact on CRO. Some investors express frustration with CRO's price action and concerns about its performance relative to other cryptocurrencies, while others remain optimistic, citing potential catalysts and partnerships.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is trending as the community buzzes about its integration with Phantom Wallet, fueling excitement. Discussions highlight the potential for a breakout and "moon" run, with many claiming bags are loaded. Some users suggest caution, comparing it to other hyped coins.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst mixed sentiments, with some community members expressing frustration over its past performance while others remain optimistic, calling for patience and a focus on long-term potential. Discussions include potential price movements and comparisons to other meme coins. The broader conversation also touches upon the overall state of the crypto market and potential market manipulation.

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is trending as community members discuss its role in bridging and burning $CAW tokens across multiple blockchains. Some users highlight a recent acquisition deal with $ZRO, while others are drawn to Stargate's integration with Hyperliquid for one-click deposits. The community is actively bridging, burning, and following the crow with knife.

MLN is the official token of Enzyme. Founded in 2017, Enzyme is the global infrastructure for tokenized finance. Enzyme provides industry leaders with a comprehensive suites of Vault-As-A-Service and Financial Instruments products to manage on-chain assets efficiently, optimize operational processes, and develop innovative financial strategies tailored to their unique goals and challenges.

Melon

Recent price action and low supply are sparking increased interest in MLN, with some community members drawing comparisons to other coins with explosive growth potential. Conversations revolve around identifying potential entry points and anticipating a significant upward move. Some traders caution about potential pump and dump schemes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months 

Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.


LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's 'Best Inventions of 2025' LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's 'Best Inventions of 2025' PR...

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.

Global Leaders Jess Mantas and Wes Bricker Join NACD Board of Directors

Global Leaders Jess Mantas and Wes Bricker Join NACD Board of Directors Global Leaders Jess Mantas and Wes Bricker Join NACD Board of Directors PR Newswire WASHINGTON, Oct. 10, 2025 Seasoned...

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today...

Can BMYs Neuroscience Portfolio Help to Diversify Its Business? 

Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.

LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy

Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.

U.S. President Donald Trump said on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting Oct. 1 unless manufacturers are actively building plants in the country.&nbsp;As part of a series of late-night posts on Truth Social on Thursday,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">Trump said</a> the exemption will apply only to firms that have “broken ground” or are “under construction.” “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”&nbsp;The announcement intensifies the administration’s push to shift drug manufacturing to the U.S. Last month, Trump said the U.S. would begin with a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">“small tariff”</a> on imported drugs before raising duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had previously been exempt from Trump’s reciprocal tariff program; however, the new duties will apply to prescription drugs, biologics, specialty medicines, and over-the-counter products, except for generic drugs, which remain excluded.Major drugmakers have responded unevenly.&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> has committed more than $50 billion since 2020 to U.S. expansion, including $27 billion for four new “mega sites.” The company supports maintaining the U.S. as the “world’s leading destination for biopharmaceutical research and manufacturing” and agrees with the administration’s goal of more fairly sharing drug costs across developed countries, even as it warns that broad tariffs could raise costs and limit access.Lilly’s stream on Stocktwits gained traction late Thursday after Trump’s announcement, with sentiment tilting ‘bullish’ as retail traders bet that the company would benefit from the latest federal policy. “$LLY did great with plant announcement in houston this week. They wont have tariffs,”&nbsp;<a href="https://stocktwits.com/Gorohanada/message/630073275">said</a> one user.Several users noted that Novo Nordisk, Regeneron and Thermo Fisher also have U.S. sites that could qualify. Some argued investors misunderstand Novo’s footprint, contributing to its recent weakness despite likely exemptions.<stembedurl>https://stocktwits.com/3rdtimeretired/message/630071784</stembedurl><stembedurl>https://stocktwits.com/Bullish_Trader555/message/630067344</stembedurl><stembedurl>https://stocktwits.com/oldmanrizzer/message/630072277</stembedurl>AstraZeneca and Roche each announced plans this summer to invest $50 billion in new or expanded facilities across multiple states. Merck has invested more than $12 billion in U.S. manufacturing since 2017 and plans to invest an additional $9 billion by 2028, while Biogen has pledged $2 billion to upgrade its North Carolina plants.Others have taken a more cautious stance. Pfizer stated in March that it could shift overseas production to existing U.S. sites if necessary, but has not committed to new investment, whereas Novo Nordisk has yet to announce major U.S. projects.&nbsp;Trump’s Thursday night post followed the launch of fresh national security probes into imports of robotics, industrial machinery, and medical devices. The Commerce Department said on Wednesday that it launched investigations on Sept. 2 to determine if these imports could pose a risk to U.S. national security.&nbsp;On Stocktwits, retail sentiment for the SPDR S&amp;P Biotech ETF (XBI) was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/XBI">XBI</a> has risen 6.5%. So far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.

Equity

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal

Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$143.00
Prev Close	$142.26
Open	$142.10
Dividend Yield	0.00%
50-Day Moving Average	$141.50
Beta	0.66
Avg. Volume	1.68M
PE Ratio	13.68

52-Week High	$190.40
52-Week Low	$110.04
Market Capitalization	$20.97B
EPS (Annual)	$11.19
Price to Book	1.19
Revenue Per Employee	$1.22M
Enterprise Value/EBITDA	N/A

BIIB
Biogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIIB News

BIIBBiogen Inc